- Home
- FMC vs OGN Comparison
FMC vs OGN Comparison
Compare FMC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- OGN
- Stock Information
- Founded
- FMC 1910
- OGN 1923
- Country
- FMC United States
- OGN United States
- Employees
- FMC N/A
- OGN N/A
- Industry
- FMC Major Chemicals
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- FMC Industrials
- OGN Health Care
- Exchange
- FMC Nasdaq
- OGN Nasdaq
- Market Cap
- FMC 4.5B
- OGN 4.0B
- IPO Year
- FMC N/A
- OGN N/A
- Fundamental
- Price
- FMC $42.17
- OGN $14.51
- Analyst Decision
- FMC Hold
- OGN Hold
- Analyst Count
- FMC 13
- OGN 5
- Target Price
- FMC $51.62
- OGN $20.80
- AVG Volume (30 Days)
- FMC 4.7M
- OGN 4.1M
- Earning Date
- FMC 04-30-2025
- OGN 05-01-2025
- Dividend Yield
- FMC 5.50%
- OGN 7.72%
- EPS Growth
- FMC N/A
- OGN N/A
- EPS
- FMC 2.71
- OGN 3.33
- Revenue
- FMC $4,246,100,000.00
- OGN $6,403,000,000.00
- Revenue This Year
- FMC N/A
- OGN N/A
- Revenue Next Year
- FMC $6.70
- OGN $1.52
- P/E Ratio
- FMC $13.17
- OGN $4.36
- Revenue Growth
- FMC N/A
- OGN 2.23
- 52 Week Low
- FMC $33.80
- OGN $13.87
- 52 Week High
- FMC $68.72
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- FMC 52.64
- OGN 40.58
- Support Level
- FMC $41.04
- OGN $14.81
- Resistance Level
- FMC $42.63
- OGN $14.81
- Average True Range (ATR)
- FMC 1.10
- OGN 0.47
- MACD
- FMC 0.33
- OGN -0.09
- Stochastic Oscillator
- FMC 64.69
- OGN 11.44
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.